Postpartum (Peripartum) Psychiatric Disorders

These three conditions form a spectrum of increasing severity following childbirth. DSM-5 classifies postpartum depression and psychosis under mood disorders "with peripartum onset" (onset during pregnancy or within 4 weeks postpartum, though clinically the window is often extended to within the first year).

1. Postpartum ("Baby") Blues

Incidence: Very common - affects up to 50-85% of women (roughly half, per most sources).

Onset/course: Begins day 2-4 postpartum, peaks around day 4-5, and is self-limited, resolving by day 10-14.

Clinical features:

Mood swings, tearfulness/crying spells, irritability, anxiety, fatigue, poor concentration, insomnia
No impairment of function, no vegetative depressive signs, no psychotic features
Considered a normal physiologic phenomenon related to the abrupt drop in estrogen/progesterone after delivery, not a psychiatric disorder

Management: Reassurance, support, and monitoring only - no specific treatment needed. Important because blues is a risk factor for later postpartum depression, so the mother should be followed up.

"The postpartum blues constitute a common, benign condition manifested as sadness, mood swings, and fatigue from days 4 to 14 after childbirth. About half of women are affected." - Swanson's Family Medicine Review

2. Postpartum Depression (PPD)

Incidence: About 10-15% of postpartum women (some sources up to 20%); most is actually a continuation of antenatal depression rather than a truly new-onset illness.

Onset: Symptoms typically peak at 10-12 weeks postpartum; DSM-5 requires onset within 4 weeks of delivery for formal "peripartum onset" specifier, but cases are diagnosed up to a year after delivery.

Clinical features:

Full major depressive episode: depressed mood, anhedonia, guilt (often centered on inadequacy as a mother), poor concentration, sleep/appetite disturbance, fatigue
Most women do NOT have prominent vegetative signs
Must be distinguished from the blues by duration (>2 weeks), severity, and functional impairment
Screening tool of choice: Edinburgh Postnatal Depression Scale

Risk factors: Personal or family history of depression, lack of partner/social support, social isolation, prior psychiatric illness, cesarean delivery, young age, low socioeconomic status, partner abuse, infant with special needs, prenatal depression.

Management:

Mild cases: psychotherapy (interpersonal therapy is well studied)
Moderate-severe cases: antidepressants - sertraline is generally considered the safest SSRI in pregnancy/lactation; paroxetine raises the most concern. Medication should not be abruptly stopped since untreated depression itself carries long-term harm to mother and child.
Brexanolone (IV, positive allosteric GABA-A modulator, an allopregnanolone analog) and zuranolone (oral) are approved specifically for postpartum depression, based on the theory that the postpartum drop in allopregnanolone (a progesterone metabolite) contributes to PPD.
ECT is safe and effective for severe, refractory, or urgent cases (e.g., with suicidality).
Breastfeeding should not be prohibited solely because of antidepressant use.

3. Postpartum (Puerperal) Psychosis

Incidence: Rare - 0.1-0.25% of births (about 1-2 per 1000 births), but a psychiatric emergency.

Onset: Abrupt, typically within the first 2 weeks postpartum (often days 3-10).

Clinical features:

Rapid-onset psychotic symptoms: delusions (often bizarre, may focus on the infant), hallucinations, disorganized behavior/thought, confusion, mood lability
Frequently the presenting picture is actually of a manic or mixed affective episode rather than a "pure" psychosis
This is NOT a benign, physiologic, or "transient" condition - it is a true psychiatric emergency with significant risk of self-harm and, critically, infanticide/harm to the infant
Women with bipolar I disorder or schizoaffective disorder constitute the largest diagnostic group - about 1 in 5 women with bipolar disorder relapse postpartum, and risk can reach 50% in those with a personal or family history of postpartum psychosis plus bipolar I/schizoaffective loading

Differential diagnosis to exclude organic causes: eclampsia, Sheehan syndrome (postpartum pituitary necrosis), thyroid disease/thyroiditis, Addison disease, electrolyte disturbance, infection/sepsis - these must always be ruled out given the abrupt onset.

Management:

Psychiatric emergency requiring hospitalization (often with the infant, in a mother-baby unit where available) to protect both mother and child
Antipsychotics and/or mood stabilizers depending on underlying diagnosis (bipolar vs. schizoaffective); ECT is effective and often used given rapid symptom control needs
Close monitoring for infanticidal/suicidal ideation is mandatory
Prophylaxis: women with bipolar disorder or a prior episode of postpartum psychosis should be considered for prophylactic mood stabilization (e.g., lithium) initiated late in pregnancy or immediately postpartum

Quick Comparison

Feature	Blues	Depression	Psychosis
Incidence	~50-85%	~10-15%	0.1-0.25%
Onset	Day 2-4	Weeks to months	Days (abrupt, ~day 3-10)
Duration	<2 weeks	Weeks-months if untreated	Emergency, needs immediate treatment
Psychotic features	No	No (unless "with psychotic features")	Yes
Treatment	Support/reassurance	Psychotherapy +/- SSRI (sertraline), brexanolone/zuranolone, ECT if severe	Hospitalization, antipsychotics/mood stabilizers, ECT
Infanticide risk	None	Low but present	Significantly elevated

Sources: Kaplan & Sadock's Comprehensive Textbook of Psychiatry; Kaplan and Sadock's Synopsis of Psychiatry; Berek & Novak's Gynecology, "Peripartum Psychiatric Disorders"; The Maudsley Prescribing Guidelines in Psychiatry, 15th ed; Rosen's Emergency Medicine; Adams and Victor's Principles of Neurology, 12th ed; Swanson's Family Medicine Review; Lippincott Illustrated Reviews Pharmacology (brexanolone).

A quick check for updated evidence: recent guideline/systematic-review literature (e.g., on zuranolone approval and updated screening recommendations) may have emerged in the last 1-2 years beyond what these textbook editions cover - let me know if you'd like me to pull the latest PubMed evidence on treatment (e.g., zuranolone trials) specifically.

This is a shared conversation. Sign in to Orris to start your own chat.